drugset / Trial / NCT05909436
Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a phase I/II study to investigate the safety, tolerability, and preliminary efficacy of GLS-012 monotherapy and in combination with GLS-010 in subjects with advanced solid rumor after progression on standard treatment.
Timeline
- Start
- 2022-10-31
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BRIVESTOBART | Monoclonal antibody | — | Intravenous |
| Subject | Zimberelimab | Monoclonal antibody | — | Intravenous |